Modus Therapeutics AB
556669-2199ActiveSwedish biotech developing sevuparin for severe inflammatory diseases.
Oversigt
- Ukendt
- Medarbejdere
- Ukendt
- Omsætning
- 2004
- Grundlagt
Nøglebeslutningstagere
John Öhd
Chief Executive Officer
Johan Dighed
Board member
Viktor Drvota
Chairman
Michael Forer
Member of the Nomination Committee
+3 flere kontakter i Funnelfeedr
Beskrivelse
Modus Therapeutics is a Swedish biotechnology company focused on developing novel treatments for severe medical conditions with high unmet needs. Their proprietary polysaccharide, sevuparin, is the core asset under development. Sevuparin is designed as a heparinoid that modifies inflammation while m...
Tags
Nøgleord
Teknologistak
Virksomhedsoplysninger
- Branche
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE556669219901
Beslutningstagere
7 kontakter i FunnelfeedrJohn Öhd
Chief Executive Officer
Johan Dighed
Board member
Viktor Drvota
Chairman
Michael Forer
Member of the Nomination Committee
Ellen Donnelly
Board Member
Claes Lindblad
CFO & Head of IR
Ellen K. Donnelly
Board Member
Lignende virksomheder
20 lignende virksomheder i FunnelfeedrSangair AB
3 medarbejdereDeveloping revolutionary blood treatment technology to combat severe sepsis infections.
ZEALAND PHARMA A/S
0 medarbejdereDeveloping peptide medicines for metabolic health challenges globally.
Disruptive Pharma AB (publ)
5–9 medarbejdereSwedish biotech developing novel kidney disease therapies based on proprietary peptides.
Abera Bioscience AB
Developing next-generation nasal vaccines using modular OMV platform technology.
bioMérieux Sweden AB
20–49 medarbejdereWorld leader developing in vitro diagnostics for health and safety.
Udforsk mere
Spørgsmål om Modus Therapeutics AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo